A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: A Hoosier oncology group study

Supportive Care in Cancer

Volumn 15, Issue 11, 2007, Pages 1285-1291

  Navari, Rudolph M ^a,b   Einhorn, Lawrence H ^c,d   Loehrer Sr , Patrick J ^c,d   Passik, Steven D ^e   Vinson, Jake ^f   McClean, John ^g   Chowhan, Naveed ^h   Hanna, Nasser H ^c,d   Johnson, Cynthia S ⁱ  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f Hoosier Oncology Group   (United States)

^g Medical and Surgical Specialists LLC   (United States)

^h Cancer Care Center   (United States)

ⁱ INDIANA UNIVERSITY   (United States)

Author keywords

Anti emetic therapy; Chemotherapy; Delayed emesis; Dexamethasone; Olanzapine; Palonosetron

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IRINOTECAN; OLANZAPINE; PALONOSETRON;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CHEMOPROPHYLAXIS; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; DRUG EFFICACY; FEMALE; HUMAN; LUNG CANCER; LYMPHANGIOSARCOMA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SINGLE DRUG DOSE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; DEXAMETHASONE; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); QUINUCLIDINES; UNITED STATES; VOMITING;

EID: 34347369980     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-007-0248-5     Document Type: Article

References (29)

1. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441-1449
2. Allison DB, Casey DE (2001) Antipsychotic-associated weight gain: a review of the literature. J Clin Psychiatry 62:22-31
3. Bloechl-Daum B, Deuson RR, Panagiotis M et al (2006) Delayed nausea and vomiting continue to reduce patients' quality of life alter highly and moderately emetogenic chemotherapy despite antiemetic treatment. J Clin Oncol 24:4472-4478
4. Bymaster FP, Calligaro D, Falcone J et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96
5. Bymaster FP, Falcone JF, Bauzon D et al (2001) Potent antagonism of 5HT3 and 5HT6 receptors by olanzapine. Eur J Pharmacol 430:341-349
6. Cleeland CS, Mendoza TR, Wang XS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89:1634-1646
7. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5HT3 receptor antagonist: results of a phase III, single dose trial versus dolasetron. Cancer 98:2473-2482
8. Eisenberg P, MacKintosh FR, Ritch P et al (2004) Efficacy, safety, and pharmacokinetics of palonosetron in patients receiving highly emetogenic, cisplatin-based chemotherapy: a dose-ranging, clinical study. Ann Oncol 15:330-337
9. Fisch MJ, Kim HF (2004) Use of atypical antipsychotic agents for symptom control in patients with advanced cancer. J Support Oncol 2:447-452
10. Goldstein LE, Sporn J, Brown S et al (1999) New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment. Psychosomatics 40:438-443
11. Gralla R, Lichinitser M, Van der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase II trial comparing single does of palonosetron with ondansetron. Ann Oncol 14:1570-1577
12. Grunberg SM, Deuson R, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern anti-emetics: perception versus reality. Cancer 100:2261-2268
13. Hale AS (1997) Olanzapine. Br J Hosp Med 58:443-445
14. Hesketh PJ, Grunberg SM, Gralla RJ et al (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind placebo-controlled trial in patients receiving high-dose cisplatin-the Aprepitant Protocol 052 Study group. J Clin Oncol 21:4112-4119
15. Mantovani G, Maccio A, Aslexandro B et al (1996) Comparison of granisetron versus ondansetron versus tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer; a randomized controlled trial. Cancer 77:941-948
16. Navari RM (2003) Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting: two new agents. J Support Oncol 1:89-103
17. Navari RM (2004) Inhibiting substance P pathway for prevention of chemotherapy-induced emesis: preclinical data, clinical trials of neurokinin-1 receptor antagonists. Support Cancer Ther 1:89-96
18. Navari RM (2006) Palonosetron: a second generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2:591-602
19. Navari RM, Einhorn LH, Loehrer PJ et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Support Care Cancer 13:529-534
20. Navari RM, Reinhardt RR, Gralla RJ et al (1999) Reduction of cisplatin-induced emesis by a selective neurokin-1 receptor antagonist. N Engl J Med 340:190-195
21. Passik SD, Kirsh KL, Theobald DE et al (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 25:485-489
22. Passik SD, Navari RM, Loehrer PJ et al (2004) A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients receiving chemotherapy. Cancer Invest 22:383-388
23. Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psych-Oncology 9:84-87
24. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD et al (2003) Addition of the neurokinin-1 receptor antagonist Aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Cancer 97:3090-3098
25. Red Book Annual Drug Topic (2006) Medical Economics Company, Montvale, NJ, pp 239-243
26. Schmoll HJ, Aapro MS, Poli-Bigelli S et al (2006) Comparison of an aprepitant regime with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000-1006
27. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559
28. Vardy J, Chiew KS, Gallica J et al (2006) Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 94:1011-1015
29. Warr DG, Hesketh PJ, Gralla RJ et al (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830